Anivive Lifesciences Unveils Breakthrough Research on Valley Fever Vaccine at World Vaccine Congress 2025 Dr. Edward Robb showcased Anivive's cutting-edge Valley Fever vaccine research at the World Vaccine Congress 2025, marking a potential breakthrough in antifungal vaccine development.

Anivive Lifesciences Unveils Breakthrough Research on Valley Fever Vaccine at World Vaccine Congress 2025 #United_States #Washington,_D.C. #Anivive #Valley_Fever #Edward_Robb

Anivive Transforms Veterinary Diagnostics with Lab Expansion Amid Growing Demand Anivive expands its Long Beach lab to meet the rising demand for specialty veterinary diagnostics, introducing cutting-edge technologies and expertise.

Anivive Transforms Veterinary Diagnostics with Lab Expansion Amid Growing Demand #United_States #Long_Beach #Anivive #Veterinary_Diagnostics #Vidium

Anivive's Generous Support for Coccidioidomycosis Study Group Meeting to Advance Fungal Disease Research Anivive announces its sponsorship of the 69th Annual Coccidioidomycosis Study Group Meeting. Learn more about their support and ongoing advancements in fungal disease research.

Anivive's Generous Support for Coccidioidomycosis Study Group Meeting to Advance Fungal Disease Research #United_States #Phoenix #vaccines #Anivive #Coccidioidomycosis

Anivive's Pivotal Study Marks Progress for Canine Lymphoma Treatment Anivive has announced the completion of a significant pivotal study for LAVERDIA®-CA1, a groundbreaking treatment for canine lymphoma, paving the way for FDA approval.

Anivive's Pivotal Study Marks Progress for Canine Lymphoma Treatment #United_States #Long_Beach #Canine_Lymphoma #Anivive #LAVERDIA